Ultragenyx Pharma (RARE) Misses Q1 EPS by 38c, provides guidance

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.84), $0.38 worse than the analyst estimate of ($1.46). Revenue for the quarter came in at $136 million versus the consensus estimate of $160.69 million.

GUIDANCE:

Ultragenyx Pharma sees FY2026 revenue of $730-760 million, versus the consensus of $746.2 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Micropolis Robotics displays autonomous robots at Dubai investment event
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight